GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » Cost of Goods Sold

ARTH (Arch Therapeutics) Cost of Goods Sold : $0.09 Mil (TTM As of Jun. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics Cost of Goods Sold?

Arch Therapeutics's cost of goods sold for the three months ended in Jun. 2024 was $0.02 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2024 was $0.09 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Arch Therapeutics's Gross Margin % for the three months ended in Jun. 2024 was 32.26%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Arch Therapeutics's Inventory Turnover for the three months ended in Jun. 2024 was 0.02.


Arch Therapeutics Cost of Goods Sold Historical Data

The historical data trend for Arch Therapeutics's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics Cost of Goods Sold Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.03 0.05 0.08

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Arch Therapeutics Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arch Therapeutics  (OTCPK:ARTH) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Arch Therapeutics's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0.031 - 0.021) / 0.031
=32.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Arch Therapeutics's Inventory Turnover for the three months ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Arch Therapeutics Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616

Arch Therapeutics Headlines

From GuruFocus